Press release
Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDAQ: AZN)
A lawsuit was filed on behalf of investors in AstraZeneca PLC (NASDAQ: AZN) shares over alleged securities laws violations.
Investors who purchased a significant amount of shares of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, have certain options and for certain investors are short and strict deadlines running. Deadline: February 21, 2025. NASDAQ: AZN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On October 30, 2024, AstraZeneca PLC disclosed that its International Executive Vice President and China President, Leon Wang, was under investigation by Chinese Authorities.
Then, on November 5, 2024, news outlets reported that a fraud investigation linked to AstraZeneca PLC had expanded to several Chinese government agencies, implicating dozens of senior executives at the Company.
Then, on December 18, 2024, Financial Times reported that Wang had been arrested and that AstraZeneca "expect[ed] to see an 'evident' revenue hit in China in the wake of the arrest," stating that "the sales impact is already very evident."
Shares of AstraZeneca PLC (NASDAQ: AZN) declined from $87.68 per share on August 30, 2024, to as low as $62.75 per share on November 18, 2024.
The plaintiff claims that between February 23, 2022 and December 17, 2024, the defendants made materially false and/or misleading statements and/or failed to disclose that AstraZeneca engaged in insurance fraud in China, that as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities, that as a result, AstraZeneca understated its legal risks, that the foregoing, once revealed, could materially harm AstraZeneca's business activities in China, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of AstraZeneca PLC (NASDAQ: AZN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDAQ: AZN) here
News-ID: 3850036 • Views: …
More Releases from Shareholders Foundation
Long-Term Investors in shares of Symbotic Inc. (NASDAQ: SYM) should contact the …
An investigation was announced for long-term investors in shares of Symbotic Inc. (NASDAQ: SYM) concerning potential breaches of fiduciary duties by certain directors of Symbotic Inc.
Investors who are current long term investors in Symbotic Inc. (NASDAQ: SYM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SYM stocks…
Investigation announced for Long-Term Investors in shares of Lululemon Athletica …
An investigation was announced for long-term investors in shares of Lululemon Athletica Inc. (NASDAQ: LULU) concerning potential breaches of fiduciary duties by certain directors and officers of Lululemon Athletica Inc.
Investors who are current long term investors in Lululemon Athletica Inc. (NASDAQ: LULU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Investors who lost money with shares of Intellia Therapeutics, Inc. (NASDAQ: NTL …
An investor, who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA), filed a lawsuit over alleged violations of Federal Securities Laws by Intellia Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and for certain investors are short and strict deadlines running. Deadline: April 14, 2025. NASDAQ: NTLA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of Elastic N.V. (NYSE: ES …
An investor, who purchased shares of Elastic N.V. (NYSE: ESTC), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Elastic N.V. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Elastic N.V. (NYSE: ESTC) have certain options and for certain investors are short and strict deadlines running. Deadline: April 14, 2025. NYSE: ESTC investors should contact the Shareholders Foundation at…
More Releases for AstraZeneca
Global Influenza Vaccines Market: Emerging Trends, Major Key Players Astrazeneca …
According to the report, The global Influenza Vaccines market is expected to grow from $ billion in 2020 to $ billion in 2028 at a CAGR of 15%.
Request Free Sample Report or PDF Copy: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=006954
The latest research report published by Evolve Business Intelligence examines the impacts of numerous market aspects on the global INFLUENZA VACCINES industry including a look at the current market size and forecasts for key segments and…
PD-1 Inhibitor Market Future Scope |Top Key Players Mentioned - Pfizer, Bristol- …
The PD-1 Inhibitor Market research report is a significant wellspring of quick information for business strategists. It gives an overall outline of the ABC industry in terms of development, cutting edge cost, income, and import /export and demand / supply information. This PD-1 Inhibitor Market report gives thorough information which improves the overall knowledge of PD-1 Inhibitor Market. The report likewise records the present market and its development possibilities in…
What's driving the Cannula Market Growth? Prominent Players Merck, AstraZeneca, …
The global cannula market is estimated to grow to USD 222.09 million by 2026 growing at a substantial CAGR during the forecast period of 2019 to 2026. The rise in market value can be factored to the growing preference of minimally invasive surgical procedures from the patients.Global Cannula Market By Product (Vascular Cannula, Cardiac Cannula, Arthroscopy Cannula, Dermatology Cannula, Nasal Cannula, Others), Type (Neonatal, Straight, Winged, Wing with Port, Winged…
PD-1 Inhibitor Market Competitive Outlook | Pfizer, Bristol-Myers Squibb, Merck …
A market study in this PD-1 Inhibitor Market report tells about the market status in the forecast period of 2020-2024. The PD-1 Inhibitor Market report helps describe the commerce strategies for the businesses of small, medium as well as large size. This PD-1 Inhibitor Market research report also offers insights into revenue generation and sustainability initiative. To achieve significant business growth and maximum return on investment (ROI), businesses must…
Exhaustive Study on Angioedema Treatment Market 2019 - 2023 | Strategic Assessme …
Global Angioedema Treatment Market report explores future trends for supply, demand and market growth rate, market size, prices, trading, competition and value chain as well as Key Players of the industry’s information with forecast from 2019 to 2023.
Global Angioedema Treatment Market Synopsis:
This report studies the Global Angioedema Treatment Market over the forecast period of 2019 to 2023. The Global Angioedema Treatment Market is expected to grow at an impressive Compound…
HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca
Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing.
Peter said:
“The…
